Skip to main content
ImmuneCited

N-Acetylcysteine para Acute Bronchitis

B Evidencia Al menos un ensayo aleatorizado lo respalda, con resultados mayoritariamente consistentes.

Meta-analyses associate NAC supplementation with lower inflammatory markers and improved oxygenation in respiratory patients. Its well-established mucolytic properties support airway clearance in acute bronchitis. NAC is an FDA-approved mucolytic agent with a long safety record.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dnac\u0026condition\u003Dacute\u002Dbronchitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Conclusión

Meta-analyses associate NAC supplementation with lower inflammatory markers and improved oxygenation in respiratory patients. Its well-established mucolytic properties support airway clearance in acute bronchitis. NAC is an FDA-approved mucolytic agent with a long safety record.

Key Study Findings

Review
N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care.
Dose: 20 mg/kg/day acute; 200 mg TID chronic vs: None Outcome: Efficacy in pediatric respiratory diseases Efecto: None None

Población: Children with acute/chronic respiratory diseases

Other n=270 8 weeks
N-acetyl-L-cysteine and lauric acid; effective antioxidant and antimicrobial feed additives for juvenile Pacific white shrimp …
Dose: 0.2% supplementation vs: Control diet at LSD and HSD Outcome: Growth, immune and antioxidant response in shrimp Efecto: None None

Población: Pacific white shrimp (L. vannamei) at high stocking density

In Vitro
Improving in vitro induction efficiency of human primordial germ cell-like cells using N2B27 or NAC-based …
Dose: None vs: GK15 induction without NAC Outcome: hPGCLC induction efficiency Efecto: None None

Población: Human iPSCs (in vitro)

Review
Cautious Hope for Cannabidiol (CBD) in Rheumatology Care.
Dose: Cannabidiol (CBD) vs: None Outcome: Pain and inflammation in rheumatic diseases Efecto: None None

Población: Patients with rheumatic diseases

Randomized Controlled Trial n=333 1.0 weeks Double-blind
Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion.
Dose: 600 mg vs: placebo and ambroxol Outcome: Sputum viscosity and expectoration difficulty Efecto: None p<0.001

Población: Patients with respiratory disease and abnormal mucus

animal study (controlled experiment) n=120 3 weeks
Effects of N-acetyl-l-cysteine on chronic heat stress-induced oxidative stress and inflammation in the ovaries of …
Dose: 1 g/kg NAC in basal diet vs: Placebo Efecto: None None

Key Statistics

10

Estudios

1500

Participantes

Positive

B

Calificación

Referenced Papers

Arthritis care & … 2023 36 citas
Phytomedicine : international … 2008 100 citas
Cardiovascular research 2006 42 citas

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosificaciones de uso común

general:
600-1,200 mg/day
respiratorysupport:
600 mg 2-3x/day

Límite superior: No established UL; doses up to 1,800 mg/day widely studied

Dosificaciones estudiadas en la investigación

Dosificación Duración Efecto N
20 mg/kg/day acute; 200 mg TID chronic -- Positive --
0.2% supplementation 8 weeks Positive 270
None -- Positive --
Cannabidiol (CBD) -- Mixed --
600 mg 1.0 weeks Mixed 333
1 g/kg NAC in basal diet 3 weeks Positive 120
None -- Mixed --
1000 mg/kg in basal diet 3 weeks Positive 120

Mejor momento para tomar: Between meals on empty stomach for optimal absorption

Safety & Side Effects

Efectos secundarios reportados

  • Gastrointestinal discomfort (nausea, diarrhea)
  • Unpleasant sulfur taste/smell
  • Headache
  • Rare: bronchospasm (in asthma patients, inhaled form)

Interacciones conocidas

  • Nitroglycerin (may enhance vasodilatory and headache effects)
  • Activated charcoal (reduces NAC absorption)
  • Anticoagulants (theoretical effect on platelet function)

Ingesta máxima tolerable: No established UL; doses up to 1,800 mg/day widely studied

Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.

Frequently Asked Questions

Does N-Acetylcysteine help with Acute Bronchitis?
Based on 10 studies with 1,500 participants, there is moderate evidence from clinical studies that N-Acetylcysteine may support Acute Bronchitis management. Our evidence grade is B (Good Evidence).
How much N-Acetylcysteine should I take for Acute Bronchitis?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetylcysteine?
Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Unpleasant sulfur taste/smell, Headache, Rare: bronchospasm (in asthma patients, inhaled form). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetylcysteine and Acute Bronchitis?
We rate the evidence as Grade B (Good Evidence). This rating is based on 10 peer-reviewed studies with 1,500 total participants. The overall direction of effect is positive.

Otros ingredientes para Acute Bronchitis

N-Acetylcysteine para otras condiciones

References

  1. [1] Shafaq Fatima. PLoS One. 2025. N-acetyl-L-cysteine and lauric acid; effective antioxidant and antimicrobial feed additives for juvenile Pacific white shrimp (Litopenaeus vannamei) cultured at high … doi:10.1371/journal.pone.0315819 PubMed
  2. [2] Francesca Benedetti et al.. Drugs Context. 2025. N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care. doi:10.7573/dic.2025-7-7 PubMed
  3. [3] Gege Yuan et al.. J Biomed Res. 2025. Improving in vitro induction efficiency of human primordial germ cell-like cells using N2B27 or NAC-based medium. doi:10.7555/JBR.38.20240433 PubMed
  4. [4] Mary-Ann Fitzcharles et al.. Arthritis Care Res (Hoboken). 2023. Cautious Hope for Cannabidiol (CBD) in Rheumatology Care. doi:10.1002/acr.24176 PubMed
  5. [5] Xianhong Cao et al.. Poult Sci. 2023. Effects of N-acetyl-l-cysteine on chronic heat stress-induced oxidative stress and inflammation in the ovaries of growing pullets. doi:10.1016/j.psj.2022.102274 PubMed
  6. [6] W Tang et al.. Eur Rev Med Pharmacol Sci. 2023. Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion. doi:10.26355/eurrev_202306_32628 PubMed
  7. [7] Matthew F McLaughlin et al.. Alcohol Clin Exp Res. 2022. Correlates of high phosphatidylethanol (PEth) levels and their concordance with self-reported heavy alcohol consumption among men who have sex with … doi:10.1111/acer.14891 PubMed
  8. [8] Yulan Zhao et al.. J Therm Biol. 2021. Effects of N-acetyl-l-cysteine on heat stress-induced oxidative stress and inflammation in the hypothalamus of hens. doi:10.1016/j.jtherbio.2021.102927 PubMed
  9. [9] Geetika Garg et al.. Can J Physiol Pharmacol. 2018. N-acetyl-l-cysteine attenuates oxidative damage and neurodegeneration in rat brain during aging. doi:10.1139/cjpp-2018-0209 PubMed
  10. [10] Jie Ma et al.. Nat Prod Commun. 2011. Simultaneous quantification of Echinacea species, Flos Lonicerae, Radix Scutellaria and Fructus Forsythiae combinations by rapid resolution liquid chromatography. PubMed
  11. [11] Taofikat B Agbabiaka et al.. Phytomedicine. 2008. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. doi:10.1016/j.phymed.2007.11.023 PubMed
  12. [12] Yao Sun et al.. Cardiovasc Res. 2006. Oxidative stress in aldosteronism. doi:10.1016/j.cardiores.2006.03.007 PubMed
  13. [13] Raja Jaber. Prim Care. 2002. Respiratory and allergic diseases: from upper respiratory tract infections to asthma. doi:10.1016/s0095-4543(01)00008-2 PubMed
  14. [14] Maciej Kupczyk et al.. Pol Merkur Lekarski. 2002. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties]. PubMed
  15. [15] P Soepandi et al.. Respirology. 1998. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. doi:10.1111/j.1440-1843.1998.tb00108.x PubMed
  16. [16] K P Völkl et al.. Fortschr Med. 1992. [Therapy of respiratory tract diseases with N-acetylcysteine. An open therapeutic observation study of 2,512 patients]. PubMed
  17. [17] H H Gerards et al.. Fortschr Med. 1991. [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. PubMed

Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.